Panax notoginseng Saponins Improve Angiogenesis in Coronary Heart Disease Based on the microRNA 200a Methylation Pathway
Jie Wang,Yan Dong,Zhaoling Li,Yun Zhang,Lanchun Liu,Guang Yang,Yongmei Liu,Jun Li,Lian Duan
DOI: https://doi.org/10.2147/dddt.s488036
IF: 4.3188
2024-12-18
Drug Design Development and Therapy
Abstract:Jie Wang, Yan Dong, Zhaoling Li, Yun Zhang, Lanchun Liu, Guang Yang, Yongmei Liu, Jun Li, Lian Duan Department of Cardiology, Guang Anmen Hospital, Beijing, People's Republic of China Correspondence: Lian Duan, Email Background: Improving angiogenesis in the ischemic myocardium is a therapeutic strategy for preventing, reducing, and repairing myocardial injury of coronary artery disease (CAD). Panax notoginseng saponins (PNS) have been widely used in the clinical treatment of cardiovascular diseases, demonstrating excellent efficacy, and can potentially improve angiogenesis in the ischemic myocardium. However, the effects of PNS on angiogenesis and its underlying mechanism of action remain unclear. Purpose: In this study, we aimed to evaluate the role of PNS in improving angiogenesis after myocardial infarction (MI) and explain the mechanism of PNS in improving angiogenesis in CAD from an epigenetic perspective. Study Design: The MI rat model was established by ligating the left anterior descending coronary artery permanently. The in vitro model comprised hypoxic human coronary artery endothelial cells (HCEACs). The mice and cells were then treated with PNS. Methods: Blood tests, histomorphology, polymerase chain reaction, enzyme-linked immunosorbent assay, Western blotting, and MassARRAY targeted methylation detection analyses were conducted in vivo and in vitro to investigate the potential mechanisms of PNS. Results: Oral PNS significantly improved myocardial injury and activated angiogenesis in MI rats. DNA methylation analysis in vitro revealed that PNS decreased the hypermethylation of microRNA 200a (miR200a). PNS improved angiogenesis in hypoxic human coronary artery endothelial cells (HCEACs) by regulating the vascular endothelial growth factor (VEGF) pathway. Conclusion: Our research shows that PNS can improve angiogenesis in rats with MI and hypoxic HCEACs and affect the level of miR200a promoter methylation and miR200a and VEGF molecular pathways. Keywords: Panax notoginseng saponins, coronary artery disease, DNA methylation, miRN200a, angiogenesis Coronary artery disease (CAD) is a serious condition that causes myocardial ischemia and hypoxia, leading to cell death. Currently, the primary treatments for CAD include drug therapy, interventional therapy, and coronary artery bypass grafting. However, for percutaneous coronary intervention the incidence of restenosis within 1 year after the intervention is as high as 33%, and the restenosis rate is even higher after 1 year. 1 There is a lack of effective treatment methods for patients with diffuse lesions at the distal end of the coronary artery, those with multivessel lesions that cannot tolerate surgery, and those in whom traditional treatment methods are poorly efficacious. 2 Therefore, improving angiogenesis in the ischemic myocardium, a therapeutic strategy for preventing, reducing, and repairing myocardial injury, remains highly anticipated. Panax notoginseng saponins (PNS) are the active ingredients of Panax notoginseng . Oral and infusion preparations of PNS have been widely used to treat cardiovascular and cerebrovascular diseases in clinic and have demonstrated excellent efficacy. 3 Notably, many studies have shown that PNS has anti-inflammatory, anti-platelet, and anti-atherosclerotic effects. Our previous randomized controlled trial (RCT) showed that PNS have good clinical efficacy in regulating lipids, stabilizing plaques, and exerting anti-inflammatory effects, which can improve angina symptoms. 4 Long-term PNS treatment can reduce the endpoint of CAD effectively. 5 The study also showed that PNS can affect microRNA (miRNA) expression and methylation. 6 However, the effects of PNS on angiogenesis and its underlying mechanism of action remain unclear. Therefore, this study aimed to evaluate the role of PNS in improving angiogenesis after myocardial infarction (MI) and explain the mechanism of PNS in improving angiogenesis in CAD from an epigenetic perspective. The preparation of the reference solution was as follows: ginsenoside R1 (no. 110745–201,921), ginsenoside Rg1 (no. 110703–2,020,034), ginsenoside Re (no. 110754–202,129,) ginsenoside Rb1 (no. 110704–202,230), and ginsenoside Rd (no. 111818–202,104), at 20 mg each, from the National Institutes for Food and Drug Control, were each placed in a 10-mL volumetric flask and dissolved as reference stock solutions. Notoginsenoside R1 and ginsenoside Rg1, Re, Rb1, and Rd were accurately measured in reserve solutions of PNS with volumes of 0.4, 1.6, 0.2, 2, and 1 mL, respectively, and placed in the same 10-mL volumetric flasks. They were then dissolved as mixed reference -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal